Lianhe Global has affirmed ‘BBB-’ global scale Long-term Issuer Credit Rating of Taizhou Huaxin Pharmaceutical Investment Co., Ltd.; Issuer Rating Outlook Stable

HONG KONG, 21 September 2022 – Lianhe Ratings Global Limited (“Lianhe Global”), an international credit rating company, has affirmed ‘BBB-’ global scale Long-term Issuer Credit Rating of Taizhou Huaxin Pharmaceutical Investment Co., Ltd. (“THPI”). The Outlook is Stable.